Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LadRx Corp LADX

Healthcare Biotechnology
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an... see more

Recent & Breaking News (OTCQB:LADX)

Breakfast Technical Briefing on Biotech Stocks -- CytRx, Aeterna Zentaris, Capricor Therapeutics, and Cymabay Therapeutics

PR Newswire August 8, 2017

CytRx Reports Second Quarter 2017 Financial Results

PR Newswire August 3, 2017

CytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An Albumin Mediated Chemotherapeutic

PR Newswire July 28, 2017

Breakfast Technical Briefing on Biotech Stocks -- CytRx, Keryx Biopharma, TG Therapeutics, and ZIOPHARM Oncology

PR Newswire June 22, 2017

CytRx Announces Reshaping of Clinical and Regulatory Executive Team

PR Newswire June 13, 2017

CytRx Announces Update on the Regulatory Pathway for Aldoxorubicin in Soft Tissue Sarcomas

PR Newswire June 8, 2017

The Most Notable Abstracts Released Ahead Of ASCO 2017

Benzinga.com  May 19, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  May 18, 2017

CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting

PR Newswire May 17, 2017

CytRx Reports First Quarter 2017 Financial Results

PR Newswire May 10, 2017

CytRx Corporation Announces Pricing of $15 Million Public Offering of Common Stock

PR Newswire April 28, 2017

CytRx Corporation Announces Proposed Public Offering of Common Stock

PR Newswire April 27, 2017

CytRx Reports 2016 Financial Results

PR Newswire March 15, 2017

CytRx to Present at the 29th Annual ROTH Conference

PR Newswire March 7, 2017

Technical Reports on Biotech Stocks -- Halozyme Therapeutics, CytRx, Cara Therapeutics, and Keryx Biopharma

PR Newswire March 2, 2017

CytRx to Present at the 19th Annual BIO CEO & Investor Conference

PR Newswire February 6, 2017

CytRx Granted Type B Pre-NDA Meeting with U.S. FDA for Registration Pathway with Aldoxorubicin as a Treatment for Patients with Relapsed Soft Tissue Sarcomas

PR Newswire January 4, 2017

Biotech Stocks on Investors' Radar -- Eleven Biotherapeutics, Illumina, Sangamo Biosciences, and CytRx

PR Newswire December 28, 2016

CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer

PR Newswire December 19, 2016

CytRx Corporation Announces $8.1 Million Registered Direct Offering of Common Stock

PR Newswire December 13, 2016